Patents by Inventor Andreas Muhs
Andreas Muhs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140079673Abstract: The invention features a method for treating or preventing ischemia in a mammal by administering unrestricted somatic stem cells (USSCs) to the mammal.Type: ApplicationFiled: November 19, 2013Publication date: March 20, 2014Applicant: ViaCord LLCInventors: Andreas MUHS, Stephan WNENDT
-
Patent number: 8673940Abstract: The present invention relates to novel compounds of formula (II) that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system. The present invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the preparation of medicaments for treating, or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins. A method of treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins is also disclosed.Type: GrantFiled: July 25, 2012Date of Patent: March 18, 2014Assignee: AC Immune SAInventors: Wolfgang Froestl, Nampally Sreenivasachary, Sophie Lohmann, Maria Pilar Lopez Deber, Andreas Muhs, Maria Pihlgren Bosch
-
Patent number: 8647631Abstract: The present invention is related to methods and pharmaceutical compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles. In particular, the invention relates to pharmaceutical composition comprising an antigenic peptide, particularly an antigenic phospho-peptide mimicking a major pathological phospho-epitope of protein tau, for the therapeutic and diagnostic use in the treatment of tauopathies including Alzheimer's Disease.Type: GrantFiled: April 1, 2010Date of Patent: February 11, 2014Assignees: Katholieke Universiteit Leuven, AC Immune S.A.Inventors: Andrea Pfeifer, Andreas Muhs, Fred Van Leuven, Maria Pihlgren
-
Patent number: 8613923Abstract: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of ?-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).Type: GrantFiled: June 12, 2008Date of Patent: December 24, 2013Assignees: AC Immune S.A., Genentech, Inc.Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
-
Patent number: 8613906Abstract: The invention features a method for treating or preventing ischemia in a mammal by administering unrestricted somatic stem cells (USSCs) to the mammal.Type: GrantFiled: May 26, 2006Date of Patent: December 24, 2013Assignee: ViaCord, LLCInventors: Andreas Muhs, Stephan Wnendt
-
Publication number: 20130287838Abstract: The method and constructs disclosed and claimed herein allow to control peptide conformation by modulation of the peptide lipidation pattern, spacer and liposome composition, or via co-administration with small molecules. Accordingly, this technology can be applied to the rational design of liposomal vaccines and for the generation of safer and more efficacious therapies for a range of human disease, in particular those based on misfolded proteins.Type: ApplicationFiled: August 12, 2011Publication date: October 31, 2013Applicant: AC Immune S.A.Inventors: David Hickman, Maria Pilar Lopez-Deber, Andreas Muhs
-
Publication number: 20130224287Abstract: The present invention relates to method for preparing liposome-based constructs comprising a peptide, particularly an antigenic peptide, of interest modified through hydrophobic moieties reconstituted in liposomes and to the antigenic constructs obtained with said method. The invention further relates to the use of said constructs for the therapeutic and diagnostic use in the treatment of diseases and disorders, which are caused by or associated with proteopathy such as Alzheimer's Disease.Type: ApplicationFiled: October 26, 2011Publication date: August 29, 2013Applicant: AC IMMUNE S.A.Inventors: Pedro Reis, David Hickman, Maria Pihlgren Bosch, Andreas Muhs, Andrea Pfeifer
-
Publication number: 20130164278Abstract: The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.Type: ApplicationFiled: August 7, 2012Publication date: June 27, 2013Applicants: Genentech, Inc., AC Immune S.A.Inventors: Andrea Pfeifer, Maria Pihtgren, Andreas Muhs, Ryan Watts
-
Publication number: 20120329149Abstract: The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.Type: ApplicationFiled: August 7, 2012Publication date: December 27, 2012Applicants: Genentech, Inc., AC Immune S.A.Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
-
Publication number: 20120309791Abstract: The present invention relates to novel compounds of formula (II) that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system. The present invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the preparation of medicaments for treating, or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins.Type: ApplicationFiled: July 25, 2012Publication date: December 6, 2012Applicant: AC IMMUNE SAInventors: Wolfgang FROESTL, Nampally Sreenivasachary, Sophie Lohmann, Maria Pilar Lopez Deber, Andreas MUHS, Maria Pihlgren Bosch
-
Publication number: 20120288896Abstract: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of ?-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).Type: ApplicationFiled: July 25, 2012Publication date: November 15, 2012Applicant: AC IMMUNE S.A.Inventors: Ruth Greferath, Andreas Muhs, Andrea Pfeifer, Claude Nicolau
-
Publication number: 20120276009Abstract: The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles. In particular, the invention relates to antibodies, which specifically recognize and bind to phosphorylated pathological protein tau-conformers and to methods and compositions involving said antibodies for the therapeutic and diagnostic use in the treatment of tauopathies including Alzheimer's Disease (AD).Type: ApplicationFiled: October 7, 2011Publication date: November 1, 2012Applicants: KATHOLIEKE UNIVERSITEIT LEUVEN, AC IMMUNE S.A.Inventors: Andrea Pfeifer, Andreas Muhs, Fred Van Leuven, Maria Pihlgren, Oskar Adolfsson
-
Publication number: 20120244165Abstract: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of ?-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).Type: ApplicationFiled: May 1, 2012Publication date: September 27, 2012Applicant: AC Immune S.A.Inventors: Ruth Greferath, Andreas Muhs, Andrea Pfeifer, Claude Nicolau
-
Patent number: 8246954Abstract: The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.Type: GrantFiled: July 23, 2009Date of Patent: August 21, 2012Assignees: AC Immune S.A., Genentech, Inc.Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
-
Publication number: 20120183599Abstract: The present invention is related to methods and pharmaceutical compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles. In particular, the invention relates to pharmaceutical composition comprising an antigenic peptide, particularly an antigenic phospho-peptide mimicking a major pathological phospho-epitope of protein tau, for the therapeutic and diagnostic use in the treatment of tauopathies including Alzheimer's Disease.Type: ApplicationFiled: April 1, 2010Publication date: July 19, 2012Applicant: AC IMMUNE S.A.Inventors: Andrea Pfeifer, Andreas Muhs, Fred Van Leuven, Maria Pihlgren
-
Publication number: 20120171216Abstract: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of ?-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).Type: ApplicationFiled: October 13, 2011Publication date: July 5, 2012Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
-
Publication number: 20120064065Abstract: The present invention is related to safe and functional antibodies for the therapeutic and diagnostic use in the treatment of an amyloidosis, a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease.Type: ApplicationFiled: July 29, 2011Publication date: March 15, 2012Inventors: Andrea Pfeifer, Andreas Muhs, Oskar Adolfsson, Ryan J. Watts
-
Patent number: 8124353Abstract: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of j3-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).Type: GrantFiled: October 2, 2007Date of Patent: February 28, 2012Assignees: AC Immune S.A., Genentech, Inc.Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
-
Publication number: 20110280808Abstract: The present invention relates to novel compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system. The present invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the preparation of medicaments for treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins. A method of treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins is also disclosed.Type: ApplicationFiled: April 18, 2011Publication date: November 17, 2011Applicant: AC Immune, S.A.Inventors: Heiko Kroth, Cotinica Hamel, Pascal Benderitter, Wolfgang Froestl, Nampally Sreenivasachary, Andreas Muhs
-
Patent number: 8048420Abstract: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of ?-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).Type: GrantFiled: June 12, 2008Date of Patent: November 1, 2011Assignees: AC Immune S.A., Genentech, Inc.Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts